From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation

Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in...

Full description

Saved in:

Bibliographic Details
Published in:	Pharmacogenomics Vol. 19; no. 10; pp. 861 - 871
Main Authors:	Salloum, Naji C, Buchalter, Erica LF, Chanani, Swati, Espejo, Gemma, Ismail, Mahjabeen S, Laine, Randy O, Nageeb, Maysaa, Srivastava, A Benjamin, Trapp, Nicholas, Trillo, Ludwig, Vance, Erica, Wenzinger, Michael, Hartz, Sarah M, David, Sean P, Chen, Li-Shiun
Format:	Journal Article
Language:	English
Published:	England Future Medicine Ltd 01-07-2018
Subjects:	Alcoholism Biomarkers Chromosomes Chronic obstructive pulmonary disease Cigarette smoking Clinical trials Cytochrome Cytochrome P-450 CYP2A6 - genetics Decision making Dopamine Dopamine D2 receptors Dopamine D4 receptors Drug addiction Drug therapy Genes Genetic diversity Genetic screening Genetic Variation Genomes Haplotypes Humans Lung cancer Nerve Tissue Proteins - genetics Nicotine Nicotine - genetics Nicotine - metabolism nicotine replacement therapy Pharmacogenetics Pharmacogenetics - trends Polymorphism Precision medicine Receptors, Nicotinic - genetics Review Smoking - genetics Smoking - physiopathology Smoking Cessation Studies Systematic review Tobacco Use Disorder - epidemiology Tobacco Use Disorder - genetics Tobacco Use Disorder - pathology Transdermal medication precision medicine nicotine replacement therapy smoking cessation pharmacogenetics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene-drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms ( ) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.
ISSN:	1462-2416 1744-8042
DOI:	10.2217/pgs-2018-0023